share_log

8-K: Current report

SEC announcement ·  Jun 13 05:27
Summary by Futu AI
On June 11, 2024, 60 Degrees Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its investigational drug tafenoquine for the treatment of acute babesiosis. This designation provides the company with benefits such as market exclusivity, tax credits, and exemption from certain FDA fees. The company has also partnered with Tufts Medical Center to conduct the first clinical trial evaluating tafenoquine's efficacy and safety in treating human babesiosis. Babesiosis is a disease transmitted by ticks, which can be severe in certain populations. The trial is set to begin recruitment on June 13, 2024, and will involve at least 24 patients. Tafenoquine is already approved for malaria prophylaxis under the name ARAKODA®. The company, which specializes in developing treatments for infectious diseases, is headquartered in Washington D.C. and has a subsidiary in Australia.
On June 11, 2024, 60 Degrees Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its investigational drug tafenoquine for the treatment of acute babesiosis. This designation provides the company with benefits such as market exclusivity, tax credits, and exemption from certain FDA fees. The company has also partnered with Tufts Medical Center to conduct the first clinical trial evaluating tafenoquine's efficacy and safety in treating human babesiosis. Babesiosis is a disease transmitted by ticks, which can be severe in certain populations. The trial is set to begin recruitment on June 13, 2024, and will involve at least 24 patients. Tafenoquine is already approved for malaria prophylaxis under the name ARAKODA®. The company, which specializes in developing treatments for infectious diseases, is headquartered in Washington D.C. and has a subsidiary in Australia.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.